Compare AT&T Inc. (T) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs TG Therapeutics Inc — how do they compare? AT&T Inc. trades at $24.29 (market cap $167.88B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: AT&T Inc. is far larger — about 22× TG Therapeutics Inc's market cap, and AT&T Inc. pays a 4.53% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| T | TGTX | |
|---|---|---|
Market Cap | $167.88B | $7.64B |
Sector | Media | Health |
52-Week High | $29.62 | $59.06 |
52-Week Low | $20.49 | $26.94 |
Enterprise Value | $313.20B | $7.84B |
Dividend Yield | 4.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $24.25, up 0.73% today, with a bullish technical signal from moving averages but overbought RSI near 77. The stock shows strong fundamentals with a P/E of 8.09, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights fiber expansion and AI partnerships, while cash flow improved to $15.12B in 2025.
Outlook is positive with a consensus price target of $27.69, offering 14% upside, supported by dividend yield near 4.7%. Risks include competition from SpaceX's Starlink and high debt levels. Analysts are mixed with 41% buy ratings, suggesting cautious optimism for value investors seeking income and steady growth.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
